MDM2 and cancer: In conjunction with these findings, the present results not only reinforce the combination of “MDM4 protein reducers” with MDM2 inhibitors as a viable approach to treating cancer cells with wild-type p53, but further provide the first insight into the mechanisms underlying these effects.